key: cord-0866158-2rphskgb
authors: Escudero, Daiana S.; Pérez, Néstor G.; Díaz, Romina G.
title: Myocardial Impact of NHE1 Regulation by Sildenafil
date: 2021-02-22
journal: Front Cardiovasc Med
DOI: 10.3389/fcvm.2021.617519
sha: 808000387bace8e43a3171974c38a2385aae9dde
doc_id: 866158
cord_uid: 2rphskgb

The cardiac Na(+)/H(+) exchanger (NHE1) is a membrane glycoprotein fundamental for proper cell functioning due its multiple housekeeping tasks, including regulation of intracellular pH, Na(+) concentration, and cell volume. In the heart, hyperactivation of NHE1 has been linked to the development of different pathologies. Several studies in animal models that reproduce the deleterious effects of ischemia/reperfusion injury or cardiac hypertrophy have conclusively demonstrated that NHE1 inhibition provides cardioprotection. Unfortunately, NHE1 inhibitors failed to reproduce these effects in the clinical arena. The reasons for those discrepancies are not apparent yet. However, a reasonable clue to consider would be that drugs that completely abolish the exchanger activity, including that its essential housekeeping function may not be the best therapeutic approach. Therefore, interventions tending to specifically reduce its hyperactive state without affecting its basal activity emerge as a novel potential gold standard. In this regard, a promising goal seems to be the modulation of the phosphorylation state of the cytosolic tail of the exchanger. Recent own experiments demonstrated that Sildenafil, a phosphodiesterase 5A inhibitor drug that has been widely used for the treatment of erectile dysfunction is able to decrease NHE1 phosphorylation, and hence reduce its hyperactivity. In connection, growing evidence demonstrates cardioprotective properties of Sildenafil against different cardiac pathologies, with the distinctive characteristic of directly affecting cardiac tissue without altering blood pressure. This mini-review was aimed to focus on the regulation of NHE1 activity by Sildenafil. For this purpose, experimental data reporting Sildenafil effects in different animal models of heart disease will be discussed.

During the last 40 years, the structure, function, and regulation of the sodium/hydrogen exchanger (NHE) have been deeply studied (1) (2) (3) . This superfamily of transporter proteins comprises 10 isoforms with different cell localization and physiological roles (4, 5) . All isoforms share the common fundamental function of protecting cells from intracellular acidification, by means of an electroneutral elimination of one intracellular H + in exchange for one extracellular Na + , and driven by the transmembrane electrochemical Na + gradient (3) . This mini review focuses on the ubiquitous isoform 1 (NHE1) of this protein family also known as the "cardiac isoform" and its regulation by the cyclic guanosine monophosphate/protein kinase G (cGMP/PKG) signaling route, triggered by inhibition of the phosphodiesterase 5A (PDE5A) by Sildenafil. THE CARDIAC NA + /H + EXCHANGER "NHE1"

The NHE1 was the first cloned isoform, the most characterized (2, 6, 7) , and the main expressed variant found in plasma membrane of mammalian cardiac cells (4) . The NHE1 is a dimeric transmembrane protein, and as other NHE isoforms, intracellular H + extrusion through the NHE1 contributes to maintain intracellular pH (pH i ) of cardiac cells in a healthy narrow range, fulfilling its crucial basal housekeeping function (3) . In fact, around normal pH i values of ∼7.2, the exchanger activity is low but enough to compensate for basal metabolic H + production. However, under certain conditions, either physiological or pathological, when pH i falls far below the normal range, the NHE1, as well as the sodium-bicarbonate cotransporter, become more active being the NHE1 the dominant alkalizing mechanism (8) . Interestingly, the recent demonstration that NHE1 is the isoform expressed in mitochondria (9) suggests a potential role of the exchanger in modulating both mitochondrial Na + and H + gradients (10) .

An exacerbated NHE1 activity has been linked to pathological cardiac processes (6) . Excessive H + efflux through NHE1 leads to a Na + -dependent Ca 2+ overload with the consequent activation of deleterious routes, including the calcium/calmodulin dependent protein kinase-histone deacetylase signaling pathway (11) , and a mitochondrial permeability transition pore (MPTP) opening (9) followed by the release of reactive oxygen species (ROS) and apoptosis (6, 12) . Hyperactivity of NHE1 has been found in several diseased states, such as ischemia/reperfusion injury (6) and postischemic cardiac remodeling (6), as well as in pressure overload (13, 14) and hypertensive (15) cardiac hypertrophy. Reinforcing all these evidences, preclinical studies have demonstrated that blunting NHE1 activity effectively provided cardioprotection in different models of heart failure (16) (17) (18) (19) . In addition, NHE1 blockade during reperfusion of hearts exposed to an ischemic insult promoted preservation of cardiac function as well as minimization of necrosis and/or apoptosis (20, 21) . The latter case is rather paradoxical. NHE1 activation after pH i fall during ischemia is necessary to preserve cell integrity. However, extracellular pH lowering due to H + extrusion under reduced blood flow, together with energetic imbalance due to deficient O 2 supply, rapidly leads to exchanger inhibition. During reperfusion, an immediate washout of extracellular H + suddenly restores NHE1 function whose hyperactivity leads to Na + and Ca 2+ overload responsible for the deleterious but distinctive effects of this phase (22) . The recovery of pH i and the subsequent Ca +2 overload results in an increased ROS release due to the MPTP opening, uncontrolled myofibrilar hypercontraction, calpain activation-mediated proteolysis, and finally apoptosis (23) .

The promising results of NHE1 inhibition in animal models prompted exploration of the clinical use of NHE1 inhibitors such as cariporide and eniporide in patients. Unfortunately, the results were far from expected, demonstrating lack or insufficient cardioprotection (24, 25) or even worse, severe side effects (26) . The reasons for these unexpected discrepancies are not apparent yet. However, the total abolition of the exchanger activity, including both its indispensable function and the pathological hyperactivation, could be a possible explanation. Despite these unforeseen results, inhibition of NHE1 is still considered the most-effective potential therapeutic approach for preventing pathological remodeling of the myocardium irrespective of its origin (27, 28) . Thus, a novel scenario of investigation would be to find interventions oriented to specifically reduce the NHE1 hyperactive state. In this regard, a promising approach seems to be the modulation of its phosphorylation level. It is necessary to be reminded that phosphorylation of the cytosolic tail of the NHE1 may either enhance (residues Ser703, Ser770, Ser771) (12, 29) or reduce (Ser 648) (30) exchanger activity. Different kinases have been linked to the phosphorylation/regulation of the NHE1. Among them, the mitogen-activated protein kinase (MAPK) route or the Ras-Raf-MEK-ERK cascade (31) activation in response to different hormones, growth factors, mechanical muscle stretch, or sustained acidosis are the most prominent ones (12, (31) (32) (33) (34) (35) (36) (37) .

Inhibitors of the cGMP-catabolizing enzyme PDE5A are known by their important vasodilatory properties. Sildenafil, among them, was developed as a promising drug against angina pectoris (38) but subsequently safely employed for the treatment of erectile dysfunction (39), pulmonary hypertension, and highaltitude pulmonary edema (40, 41) . The main action of Sildenafil was originally assigned to vasodilation and attributed to the increase in the endothelial nitric oxide (NO)-cGMP pathway (42, 43) , even in pulmonary hypertension (40) . Basal PDE5A expression in cardiac tissue was initially considered insufficient to be detected (44) , but further evidence demonstrated that PDE5A is a ubiquitous enzyme (45) and that the myocardium has baseline PDE5A activity (46) . Moreover, recent studies showed that upregulation of cardiac PDE5A expression was tightly associated to failing (47, 48) and hypertrophic (49) hearts, to ischemic left and right ventricles (47) , and also to the lethal congenital disease known as failing single ventricle (50) . In addition, an increased PDE5A expression has been found in different cardiomyopathies that lead to heart failure, such as Chagas (51), or burn-induced (52) cardiac disease. For the specific objective of our current review, PDE5A overexpression has been linked to oxidative stress and the development of pressure overload-triggered myocardial hypertrophy (53, 54) , conditions that clearly resemble NHE1 hyperactivation (6) . Taken together, the experimental evidence encourages considering that PDE5A inhibition may conceivably be a suitable target to treat cardiac pathologies.

The pharmacological target of Sildenafil is PDE5A, with high isozyme selectivity (43) . The three PDE5A splicing variants showed equal activity in terms of cGMP-hydrolytic breakdown, as well as similar sensitivity to the inhibition by Sildenafil (45) . Due to the structural similarity with cGMP, Sildenafil competitively interacts and inhibits PDE5A enzyme, with the consequent increase in cGMP levels (43) . This second messenger binds to PKG, producing an allosteric structural change in the kinase that leads to thiol oxidation, inducing a disulfide homodimer, hence activating the kinase (55) . A well-known consequence of PDE5A inhibition is the activation of Ca +2dependent K + channels (BK Ca ) (43) . However, novel actions of Sildenafil will be discussed below.

Sildenafil was found to trigger a direct NHE1 inhibitory action in rat (56, 57) and cat (58) myocardium following sustained intracellular acidosis (Figure 1) , and also in the setting of ischemia/reperfusion injury in isolated rat hearts (60) . It has been demonstrated that the cGMP/PKG route also regulates different NHE isoforms in different tissues (61, 62) . In our hands, inhibition of the NHE1 hyperactivity by acute Sildenafil intervention was due to phosphatase-mediated Ser703 dephosphorylation (57, 58, 60) . Importantly, acute NHE1 inhibition by Sildenafil did not affect its basal phosphorylation or expression, and hence preserved its critical homeostatic function (56, 57) . This posttranslational regulation of the exchanger was found only after sustained acidosis and was canceled by PKG inhibitors (56) . In apparent contradiction to our results, Richards et al. (63) reported two different routes for cGMP-triggered NHE1 regulation according to NO concentration. Using an aminoacidic sequence that reproduced the C-terminal of the NHE1, they showed that high NO concentration triggers PKAmediated Ser648 phosphorylation, while low NO concentration leads to PKG-mediated Ser703 phosphorylation (63) . Although speculative, and thinking in terms of dimeric kinases-mediated phosphorylation (such as PKG and PKA actions), the fact that the authors used part of the whole NHE1 molecule composes a completely different experimental scenario that would condition any possibility of comparison.

We have also demonstrated that the inhibitory effect of Sildenafil on the NHE1 requires activation of the p38MAPK (Figure 1) , since blockade of this kinase canceled the inhibitory effect of Sildenafil on the exchanger (59) . The exact sequence of events triggered by Sildenafil seems to be as follows: cGMP/PKG activation increase after PDE5A inhibition; p38MAPK phosphorylation/activation by PKG (64); p38MAPKtriggered PP2A assembling (65) and migration to sarcolemmal membrane (66) ; NHE1 dephosphorylation at Ser703 by PP2A (67); inhibition of NHE1 hyperactivity (57) . See Figure 2 for details. Another controversial subject is the possible role of acute Sildenafil on ROS. In this regard, it has been shown that this drug did not reduce ROS-induced lipid peroxidation in hearts subjected to regional ischemia/reperfusion (60) but reduced mitochondrial H 2 O 2 production under ischemia (68, 69) . Despite possible differences in the sensitivity of experimental methods, ROS-sensitive kinases remained enhanced even after short incubation with Sildenafil, strategy that was enough to effectively inhibit the NHE1 (60). Longer time periods of Sildenafil incubation or preischemic application of the drug conducted to a marked reduction of ROS (68) (69) (70) .

Different studies were aimed to explain the subcellular basis of the beneficial actions of chronic PDE5A inhibition by Sildenafil in the myocardium. Among them, it is interesting to recall the described inhibitory effect on voltage-operated L-type Ca +2 channels (71) , and on the transient receptor potential channels (TRPC) (72) , with the consequent decrease in intracellular Ca 2+ , therefore eluding the calcium/calmodulin-NFAT pro-apoptotic pathway (73) . The results obtained in our own laboratory add a new piece of knowledge about Sildenafil anti-hypertrophic and anti-apoptotic effect, since its previously unknown inhibitory effect on NHE1 hyperactivity provides an additional clue to understand how this kind of drug can prevent calcium overload. Regarding the modulation of NHE1 activity as a potential therapeutic target, it was reported that complete and chronic blockade of the exchanger triggers protein upregulation to escape from inhibition (74) . Interestingly, chronic treatment of infarcted hearts with Sildenafil did not follow this rule by decreasing NHE1 expression (56) .

The possibility that chronic effects of Sildenafil could also involve mitochondrial actions should be considered. Chronic Sildenafil treatment improved respiratory rate and reduced ROS production (51) . These effects were attributed to restoration of mitochondrial DNA-encoded gene expression (51), activation of mitochondrial BK Ca channels (68), prevention of MPTP opening (75) , and/or maintenance of mitochondrial membrane involving a sequential activation of p38MAPK and PP2A. Right panel: Chronic Sildenafil effects includes inhibition of TRPC and L-type Ca +2 channels, and prevention of NHE1 hyperactivation, all together leading to a decrease in the Ca +2 overload-triggered calcineurin/NFAT deleterious pathway. Furthermore, mitochondrial actions of Sildenafil involving mBK Ca channel opening, mNHE1 inhibition, and membrane potential maintenance reduce the probability of MPTP opening and ROS release, contributing to cardioprotection. potential (76) . In connection, it is important to be reminded that a decrease in mitochondrial NHE1 expression/activity preserves an acidic environment around mitochondria, therefore diminishing Ca +2 -induced mitochondrial swelling (9) . In addition, it was shown that inhibition of MPTP opening leads to a decrease in ROS production after ischemia (77) . Considering these results as a whole, the question as to whether Sildenafil could regulate mitochondrial NHE1 certainly arises. In this regard, recent experiments in the hypertrophied myocardium of SHR suggested that a decreased ROS production after chronic Sildenafil treatment may conceivably result from inhibition of mitochondrial NHE1 through a reduction in its phosphorylation state (78) . Figure 2 summarizes putative signaling pathways triggered by Sildenafil.

As it was mentioned in a previous section, since the approval and commercialization of Sildenafil more than two decades ago (79) , the pharmacodynamics of this drug has been extended to different pathological therapeutic targets. Actually, it has been studied for the treatment of different types of cancers (80) , Alzheimer disease (81), vascular dementia (82) , and also recently proposed to treat COVID-19 patients (83) . Regarding cardiac pathologies, Sildenafil showed the ability to prevent and/or reverse cardiac remodeling induced by acute myocardial infarction (56) , chronic mitral regurgitation (84) , or pressure overload (85, 86) . Additional benefits of Sildenafil were attenuation of sympathetic hyperinnervation (87) and promotion of an increase in the QT interval (88), therefore reducing the incidence of ischemia-induced arrhythmia. Concerning to other causes of cardiac morbidity, Sildenafil reverted (89), or prevented (52, 85, 90, 91) , cardiac fibrosis development regardless of its origin. Furthermore, improvement of heart failure by PDE5 inhibition was shown to involve attenuation of chronotropic response to dobutamin and a T-tubule network restoration (92) . Importantly, different studies under diverse experimental conditions demonstrated that the beneficial cardiac effects of Sildenafil are independent of blood pressure (78, 84, 86) .

We have briefly reviewed the role of Sildenafil on NHE1 regulation and its possible pathophysiological relevance. Classical Sildenafil targets were presented, but the main focus of this revision was centered on the novel inhibitory action of this drug on the NHE1. We were particularly interested in stressing the potential benefits of specifically targeting NHE1 hyperactivity, avoiding its complete blockade, which suggests that Sildenafil treatment would be a better therapeutic approach than traditional NHE1 blockers in the field of cardiology.

Finally, considering that Sildenafil has been safely used during more than two decades (39) and that recent results in heart failure patients are certainly promising (93), we suggest that Sildenafil treatment would represent an appropriate opportunity for immediately access to a less expensive and more secure novel therapeutic alternative to treat severe cardiac pathologies characterized by exacerbated NHE1 activity.

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

PICT 2017-4543 from Agencia Nacional de Promoción Científica y Técnica to RD. PICT 2016-2289 from Agencia Nacional de Promoción Científica y Técnica to NP.

An investigation of the ionic mechanism of intracellular pH regulation in mouse soleus muscle fibres

Molecular cloning, primary structure, and expression of the human growth factor-activatable Na+/H+ antiporter

The Na(+) /H(+) exchanger and pH regulation in the heart

Diversity of the mammalian sodium/proton exchanger SLC9 gene family

NHE10, an osteoclastspecific member of the Na+/H+ exchanger family, regulates osteoclast differentiation and survival

The myocardial Na(+)-H(+) exchange: structure, regulation, and its role in heart disease

Structure and function of the NHE1 isoform of the Na+/H+ exchanger

pH-Regulated Na(+) influx into the mammalian ventricular myocyte: the relative role of Na(+)-H(+) exchange and Na(+)-HCO Co-transport

Silencing of cardiac mitochondrial NHE1 prevents mitochondrial permeability transition pore opening

Regulation of intracellular and mitochondrial sodium in health and disease

Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure

Sustained intracellular acidosis activates the myocardial Na(+)/H(+) exchanger independent of amino acid Ser(703) and p90(rsk)

Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy

Activated NHE1 is required to induce early cardiac hypertrophy in mice

pHi regulation in myocardium of the spontaneously hypertensive rat

Na(+)/H(+) exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats

Regression of cardiomyocyte hypertrophy in SHR following chronic inhibition of the Na(+)/H(+) exchanger

Regression of hypertensive myocardial fibrosis by Na(+)/H(+) exchange inhibition

Chronic NHE-1 blockade induces an antiapoptotic effect in the hypertrophied heart

Orally administered NHE1 inhibitor cariporide reduces acute responses to coronary occlusion and reperfusion

Sodium-hydrogen exchanger isoform-1 inhibition: a promising pharmacological intervention for resuscitation from cardiac arrest

Na+/H+ exchangers: physiology and link to hypertension and organ ischemia

Calcium-mediated cell death during myocardial reperfusion

Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial Guard during ischemia against necrosis (GUARDIAN) Investigators

The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial

Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study

NHE-1: still a viable therapeutic target

Silencing of the Na(+)/H(+) exchanger 1(NHE-1) prevents cardiac structural and functional remodeling induced by angiotensin II

Regulatory effects of G protein-coupled receptors on cardiac sarcolemmal Na+/H+ exchanger activity: signalling and significance

Protein kinase B/Akt phosphorylates and inhibits the cardiac Na+/H+ exchanger NHE1

ERK: a key player in the pathophysiology of cardiac hypertrophy

Angiotensin II-stimulated Na+/H+ exchange in cultured vascular smooth muscle cells. Evidence for protein kinase

C-dependent and -independent pathways

Aldosterone activates Na+/H+ exchange in vascular smooth muscle cells by nongenomic and genomic mechanisms

p90(RSK) is a serum-stimulated Na+/H+ exchanger isoform-1 kinase. Regulatory phosphorylation of serine 703 of Na+/H+ exchanger isoform-1

Stimulation of the plasma membrane Na+/H+ exchanger NHE1 by sustained intracellular acidosis. Evidence for a novel mechanism mediated by the ERK pathway

A low dose of angiotensin II increases inotropism through activation of reverse Na(+)/Ca(2+) exchange by endothelin release

Epidermal growth factor activates Na(+/)H(+) exchanger in podocytes through a mechanism that involves Janus kinase and calmodulin

Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective

Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease

Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxiainduced lung injury

Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial

Molecular mechanisms of the effects of sildenafil (VIAGRA)

Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction

The emperor's new clothes: PDE5 and the heart

Tissue expression, distribution, and regulation of PDE5

Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes

Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice

Differential expression of PDE5 in failing and nonfailing human myocardium

Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling

Phosphodiesterase-5 is elevated in failing single ventricle myocardium and affects cardiomyocyte remodeling in vitro

Chemotherapeutic efficacy of phosphodiesterase inhibitors in chagasic cardiomyopathy

Sildenafil recovers burn-induced cardiomyopathy

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5

Mechanisms associated with cGMP binding and activation of cGMPdependent protein kinase

Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction

Phosphodiesterase 5A inhibition decreases NHE-1 activity without altering steady state pH(i): role of phosphatases

Decreased activity of the Na+/H+ exchanger by phosphodiesterase 5A inhibition is attributed to an increase in protein phosphatase activity

p38 mitogen activated protein kinase mediates cardiac Na+/H+ exchanger inhibition induced by Sildenafil

Myocardial reperfusion injury: reactive oxygen species vs. NHE-1 reactivation

Natriuretic peptides and diadenosine polyphosphates modulate pH regulation of rat mesangial cells

Regulation of NHE3 by nitric oxide in Caco-2 cells

Nitric oxide modulates cardiomyocyte pH control through a biphasic effect on sodium/hydrogen exchanger-1

Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of the platelet integrin alphaIIb beta3

Modulation of protein phosphatase 2a by adenosine A1 receptors in cardiomyocytes: role for p38 MAPK

Negative regulation of Akt activity by p38alpha MAP kinase in cardiomyocytes involves membrane localization of PP2A through interaction with caveolin-1

A novel role for protein phosphatase 2A in receptor-mediated regulation of the cardiac sarcolemmal Na+/H+ exchanger NHE1

Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits

Thioredoxin-1 is required for the cardioprotecive effect of sildenafil against ischaemia/reperfusion injury and mitochondrial dysfunction in mice

Impact of mitochondrial Ca2+-sensitive potassium (mBKCa) channels in sildenafil-induced cardioprotection in rats

Effects of sildenafil on cardiac repolarization

Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition

Inhibition of calcineurin-NFAT hypertrophy signaling by cGMPdependent protein kinase type I in cardiac myocytes

Upregulation of myocardial Na+/H+ exchanger induced by chronic treatment with a selective inhibitor

Stress-induced opening of the permeability transition pore in the dystrophindeficient heart is attenuated by acute treatment with sildenafil

Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity

Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection

PDE5 inhibition improves cardiac morphology and function in SHR by reducing NHE1 activity: repurposing Sildenafil for the treatment of hypertensive cardiac hypertrophy

Patterns of use of sildenafil among commercially insured adults in the United States: 1998-2002

Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents

Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease

Sildenafil treatment of vascular dementia in aged rats

Phosphodiesterase type 5 inhibitors and COVID-19: are they useful in disease management?

Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo

Effect of sildenafil on ventricular arrhythmias in post-infarcted rat hearts

Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs

Prevention of PKG-1alpha oxidation suppresses antihypertrophic/antifibrotic effects from PDE5 inhibition but not sGC stimulation

Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor beta-induced Smad signaling

Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis

Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure

PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study